Metformina Ratiopharm (Metformin Hydrochloride)

Metformin acts primarily by inhibiting hepatic gluconeogenesis, thereby decreasing the amount of glucose released into the bloodstream. It also enhances peripheral insulin sensitivity, promoting greater uptake of glucose by muscle and fat cells, and modestly reduces intestinal glucose absorption.

The exact dose of Metformina Ratiopharm is set by the prescribing clinician based on individual factors such as the patient’s age, renal function, glycemic targets, and response to therapy. No fixed regimen is provided here; dosing decisions are made on a case‑by‑case basis.

Safety data for metformin in pregnancy are limited, and the drug is generally not recommended unless the potential benefit outweighs the risk. Metformin is excreted in breast milk, so caution is advised for nursing mothers, and a healthcare professional should evaluate the situation.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformina Ratiopharm (metformin) belongs to the biguanide class and is often first‑line therapy for type 2 diabetes because of its efficacy, low risk of hypoglycemia, and weight‑neutral profile. Compared with sulfonylureas, it does not cause insulin release, and unlike insulin, it is administered orally.

Metformina Ratiopharm should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Metformina Ratiopharm is taken orally, usually with a glass of water. It can be taken with meals to reduce gastrointestinal discomfort. The exact timing and frequency are determined by the prescribing clinician based on the patient’s therapeutic plan.

The most serious adverse events include lactic acidosis, a rare but potentially fatal condition, and severe hypoglycemia when metformin is combined with other glucose‑lowering drugs. Prompt medical attention is required if symptoms such as unexplained fatigue, rapid breathing, or abdominal pain occur.

Metformina Ratiopharm is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and in those with conditions that predispose to hypoxia, such as significant cardiac or respiratory disease.